scholarly journals Barriers and Motivators to Participation in Human Immunodeficiency Virus (HIV) Clinical Trials of Persons Living With HIV in the Southern United States

2015 ◽  
Vol 2 (suppl_1) ◽  
Author(s):  
Prema Menezes ◽  
Kea Turner ◽  
Jessica Margolis ◽  
Cheryl Marcus ◽  
Joseph Eron ◽  
...  
2008 ◽  
Vol 3 (1) ◽  
pp. 79-84 ◽  
Author(s):  
Xiao Xu ◽  
Divya A. Patel ◽  
Vanessa K. Dalton ◽  
Mark D. Pearlman ◽  
Timothy R. B. Johnson

Primary prevention of human immunodeficiency virus (HIV) continues to pose an important challenge in the United States. Recent clinical trials conducted in Kenya, South Africa, and Uganda have demonstrated considerable benefit of male circumcision in reducing HIV seroincidence in males. These results have ignited debate over the appropriateness of implementing routine provision of neonatal circumcision in the United States for HIV prevention. This article discusses major contextual differences between the United States and the three African countries where the clinical trials were conducted, and cautions that the applicability of the scientific data from Africa to this country must be carefully considered before rational policy recommendations regarding routine neonatal circumcision can be made as a strategy to prevent the spread of HIV in the United States.


CORD ◽  
2000 ◽  
Vol 16 (02) ◽  
pp. 34
Author(s):  
Eric A. Tayag ◽  
Edna G. Santiago ◽  
Minda A. Manado ◽  
Perla N. Alban ◽  
Dorothy Mae Agdamag ◽  
...  

The AIDS pandemic has caused global concern what with its threat to man’s survival and the enormous cost to prevent and treat the illness. No effective cure is possible but for the last fifteen years, countless studies were made to improve survival, delay disease progression or just improve the quality of life. Various clinical trials were designed to inhibit specific processes that are necessary for the human immunodeficiency virus (HIV) to survive the internal milieu. As important as these discoveries, are the precise methods of measuring the impact of these treatments. Only in the last five years has there been a better understanding of these processes and methods.


Author(s):  
Paul Krogstad ◽  
Pearl Samson ◽  
Edward P Acosta ◽  
Jack Moye ◽  
Ellen Townley ◽  
...  

Abstract Pharmacological interactions limit treatment options for children living with human immunodeficiency virus (HIV) and tuberculosis (TB). We found that 12 mg/kg twice daily raltegravir chewable tablets (administered after crushing) safely achieved pharmacokinetic targets in children living with HIV aged 4 weeks to <2 years receiving concurrent rifampin to treat TB. Clinical Trials Registration NCT01751568.


2017 ◽  
Vol 65 (10) ◽  
pp. 1601-1606 ◽  
Author(s):  
R Douglas Bruce ◽  
Jessica Merlin ◽  
Paula J Lum ◽  
Ebtesam Ahmed ◽  
Carla Alexander ◽  
...  

Abstract Pain has always been an important part of human immunodeficiency virus (HIV) disease and its experience for patients. In this guideline, we review the types of chronic pain commonly seen among persons living with HIV (PLWH) and review the limited evidence base for treatment of chronic noncancer pain in this population. We also review the management of chronic pain in special populations of PLWH, including persons with substance use and mental health disorders. Finally, a general review of possible pharmacokinetic interactions is included to assist the HIV clinician in the treatment of chronic pain in this population. It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. The Infectious Diseases Society of American considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient’s individual circumstances.


Author(s):  
Peter A. Newman

AIDS (acquired immunodeficiency syndrome) is the most deadly epidemic of modern times. Since HIV (human immunodeficiency virus), the virus that causes AIDS, was first identified in the United States in 1981, nearly 1 million Americans have been diagnosed with AIDS and 530,756 have died. Forty million people are living with HIV worldwide. Although AIDS is still a fatal disease, new drug therapies have greatly slowed the course of disease progression and enhanced quality of life for persons living with HIV. Nevertheless, monumental disparities persist within the United States and between the developed and developing worlds in this two-tiered epidemic.


Author(s):  
Rose S Bono ◽  
Bassam Dahman ◽  
Lindsay M Sabik ◽  
Lauren E Yerkes ◽  
Yangyang Deng ◽  
...  

Abstract Background Human immunodeficiency virus (HIV)–experienced clinicians are critical for positive outcomes along the HIV care continuum. However, access to HIV-experienced clinicians may be limited, particularly in nonmetropolitan areas, where HIV is increasing. We examined HIV clinician workforce capacity, focusing on HIV experience and urban–rural differences, in the Southern United States. Methods We used Medicaid claims and clinician characteristics (Medicaid Analytic eXtract [MAX] and MAX Provider Characteristics, 2009–2011), county-level rurality (National Center for Health Statistics, 2013), and diagnosed HIV cases (AIDSVu, 2014) to assess HIV clinician capacity in 14 states. We assumed that clinicians accepting Medicaid approximated the region’s HIV workforce, since three-quarters of clinicians accept Medicaid insurance. HIV-experienced clinicians were defined as those providing care to ≥ 10 Medicaid enrollees over 3 years. We assessed HIV workforce capacity with county-level clinician-to-population ratios, using Wilcoxon-Mann-Whitney tests to compare urban–rural differences. Results We identified 5012 clinicians providing routine HIV management, of whom 28% were HIV-experienced. HIV-experienced clinicians were more likely to specialize in infectious diseases (48% vs 6%, P < .001) and practice in urban areas (96% vs 83%, P < .001) compared to non–HIV-experienced clinicians. The median clinician-to-population ratio for all HIV clinicians was 13.3 (interquartile range, 38.0), with no significant urban–rural differences. When considering HIV experience, 81% of counties had no HIV-experienced clinicians, and rural counties generally had fewer HIV-experienced clinicians per 1000 diagnosed HIV cases (P < .001). Conclusions Significant urban–rural disparities exist in HIV-experienced workforce capacity for communities in the Southern United States. Policies to improve equity in access to HIV-experienced clinical care for both urban and rural communities are urgently needed.


2019 ◽  
Vol 71 (5) ◽  
pp. 1300-1305 ◽  
Author(s):  
Laura M Smeaton ◽  
Deborah Kacanek ◽  
Kateryna Mykhalchenko ◽  
Kristine Coughlin ◽  
Karin L Klingman ◽  
...  

Abstract Background Women are underrepresented in human immunodeficiency virus (HIV) research in the United States. To determine if women screening for HIV clinical trials enrolled at lower rates than men, we performed a retrospective, cross-trial analysis. Methods We conducted an analysis of screening and enrollment during 2003–2013 to 31 clinical trials at 99 AIDS Clinical Trials Group network research sites in the United States. Random-effects meta regression estimated whether sex differences in not enrolling (“screen out”) varied by various individual, trial, or site characteristics. Results Of 10 744 persons screened, 18.9% were women. The percentages of women and men who screened out were 27.9% and 26.5%, respectively (P = .19); this small difference did not significantly vary by race, ethnicity, or age group. Most common reasons for screening out were not meeting eligibility criteria (30–35%) and opting out (23%), and these did not differ by sex. Trial and research site characteristics associated with variable screen-out by sex included HIV research domain and type of hemoglobin eligibility criterion, but individual associations did not persist after adjustment for multiple testing. Conclusions In the absence of evidence of significantly higher trial screen-out for women, approaching more women to screen may increase female representation in HIV trials.


Sign in / Sign up

Export Citation Format

Share Document